Zobrazeno 1 - 10
of 44
pro vyhledávání: '"JOHN H. HEILIGENSTEIN"'
Autor:
S. Kaplan, Donald Harder, John H. Heiligenstein, Charles D. Casat, Stephen G. West, J. Busner, Ralf W. Dittmann, J. F. Wernicke
Publikováno v:
Journal of Attention Disorders. 8:45-52
Objective: To compare the safety and efficacy of atomoxetine, a selective inhibitor of the norepinephrine transporter, versus placebo in Attention-Deficit/Hyperactivity Disorder (ADHD) patients with comorbid Oppositional Defiant Disorder (ODD). Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::896d544ec4add9c6ae071e47b4626e73
https://doi.org/10.1177/108705470400800202
https://doi.org/10.1177/108705470400800202
Publikováno v:
Journal of Child and Adolescent Psychopharmacology. 14:412-417
The aim of this study was to assess the safety of subchronic fluoxetine treatment for major depressive disorder (MDD) in children and adolescents.Patients received up to 19 weeks of treatment with fluoxetine, 10 mg-60 mg daily. Safety was evaluated t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ae87fc45314d3c82413eac471fbb6be
https://doi.org/10.1089/cap.2004.14.412
https://doi.org/10.1089/cap.2004.14.412
Autor:
Joachim F. Wernicke, David Michelson, John H. Heiligenstein, Haitao Gao, Donald A. Girod, Jeffrey W. Brown, Humberto Quintana, Douglas E. Faries, Douglas Kelsey, Robert Lipetz
Publikováno v:
Drug Safety. 26:729-740
Background: Atomoxetine is a highly specific presynaptic inhibitor of the noradrenaline (norepinephrine) transporter that was recently approved in the US for the treatment of patients with attention-deficit/hyperactivity disorder (ADHD). Adverse effe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71e3286c1cf821df801c6450ddee3bb4
https://doi.org/10.2165/00002018-200326100-00006
https://doi.org/10.2165/00002018-200326100-00006
Autor:
John H. Heiligenstein, Joseph Biederman, Christopher J. Kratochvil, William Z. Potter, Douglas E. Faries, Thomas J. Spencer, C. Keith Conners
Publikováno v:
The Journal of Clinical Psychiatry. 63:1140-1147
Background: Atomoxetine is a nonstimulant drug being studied for the treatment of attention-deficit/hyperactivity disorder (ADHD). Atomoxetine is a highly specific inhibitor of the presynaptic norepinephrine transporter with minimal affinity for othe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76aef53185fd69c22ae498ccb04802ab
https://doi.org/10.4088/jcp.v63n1209
https://doi.org/10.4088/jcp.v63n1209
Autor:
John H. Heiligenstein, S Michelle Morin, Kenneth W. Perry, David L. Nelson, Frank P. Bymaster, Susan K. Hemrick-Luecke, Penny G. Threlkeld, Jason Katner, Donald R. Gehlert
Publikováno v:
Neuropsychopharmacology. 27:699-711
The selective norepinephrine (NE) transporter inhibitor atomoxetine (formerly called tomoxetine or LY139603) has been shown to alleviate symptoms in Attention Deficit/Hyperactivity Disorder (ADHD). We investigated the mechanism of action of atomoxeti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2560787461674209177e16adedfef567
https://doi.org/10.1016/s0893-133x(02)00346-9
https://doi.org/10.1016/s0893-133x(02)00346-9
Autor:
Sharon L. Hoog, Karen Dineen Wagner, Daniel E. Ernest, Jennie G. Jacobson, John H. Heiligenstein, Mary E. Nilsson, Graham J. Emslie, Eileen Brown
Publikováno v:
Journal of the American Academy of Child & Adolescent Psychiatry. 41:1205-1215
This report presents results from the acute treatment phase of a clinical trial designed to confirm efficacy of a fixed dose of 20 mg of fluoxetine in children and adolescents with major depressive disorder (MDD).After a 3-week screening period, 122
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::682aa161569274faa5cf3f6ca396a84d
https://doi.org/10.1097/00004583-200210000-00010
https://doi.org/10.1097/00004583-200210000-00010
Publikováno v:
Journal of Clinical Psychopharmacology. 21:561-568
The 1-week single-blind placebo lead-in has long been a standard in double-blind psychopharmacology clinical trials. Although a lead-in period is often necessary (e.g., to receive laboratory results before randomization), some authors have demonstrat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08b50e3cb712b464a6a290ec0974b8b5
https://doi.org/10.1097/00004714-200112000-00004
https://doi.org/10.1097/00004714-200112000-00004
Publikováno v:
Journal of Attention Disorders. 5:107-115
There are several parent- and teacher-scored rating scales that are validated and available for assessing the severity of ADHD symptoms in pediatric populations. However, we are not aware of any symptom severity rating scales with published validatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b391284e50e86779deb93bf1c3e93091
https://doi.org/10.1177/108705470100500204
https://doi.org/10.1177/108705470100500204
Autor:
DANIEL A. GELLER, SHARON L. HOOG, JOHN H. HEILIGENSTEIN, RANDALL K. RICARDI, ROY TAMURA, STACY KLUSZYNSKI, JENNIE G. JACOBSON, null FLUOXETINE PEDIATRIC OCD STUDY TEAM
Publikováno v:
Journal of the American Academy of Child & Adolescent Psychiatry. 40:773-779
Objective This study assesses the efficacy and tolerability of fluoxetine in the acute treatment of child and adolescent obsessive-compulsive disorder (OCD) during a 13-week, double-blind, placebo-controlled study. Method Eligible patients aged 7 to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a2886e5cf66948959ab1c1d62dd3f59
https://doi.org/10.1097/00004583-200107000-00011
https://doi.org/10.1097/00004583-200107000-00011
Publikováno v:
Psycho-Oncology. 7:291-300
Background. This study was conducted to determine the efficacy and tolerability of fluoxetine and desipramine in treating depressive symptoms in women with cancer. Method. In this prospective, 6-week, double-blind, placebo-controlled trial, we compar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ddd96cc390811b710cfb704fbd3400c
https://doi.org/10.1002/(sici)1099-1611(199807/08)7:4<291::aid-pon361>3.0.co
https://doi.org/10.1002/(sici)1099-1611(199807/08)7:4<291::aid-pon361>3.0.co